1. Home
  2. NGNE

as 11-21-2024 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Founded: 2003 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 471.1M IPO Year: N/A
Target Price: $60.80 AVG Volume (30 days): 539.5K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.26 EPS Growth: N/A
52 Week Low/High: $12.49 - $74.49 Next Earning Date: 11-18-2024
Revenue: $925,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

NGNE Daily Stock ML Predictions

Share on Social Networks: